title: NK-1 receptor desensitization and neutral endopeptidase terminate SP-induced pancreatic plasma extravasation.
abstract: Substance P (SP) induces plasma extravasation and neutrophil infiltration by activating the neurokinin-1 receptor (NK1-R). We characterized the mechanisms regulating this response in the rat pancreas. Anesthetized rats were continuously infused with SP, and plasma extravasation was quantified using Evans blue (EB) dye. Continuous infusion of SP (8 nmol. kg(-1). h(-1)) resulted in a threshold increase in EB at 15 min, a peak effect at 30 min (150% increase), and a return to baseline by 60 min. The NK1-R antagonist CP-96,345 blocked SP-induced plasma extravasation. After 60 min, the NK1-R was desensitized to agonist challenge. Resensitization was first detected at 20 min and increased until full recovery was seen at 30 min. Inhibition of the cell-surface protease neutral endopeptidase (NEP) by phosphoramidon potentiated the effect of exogenous SP; therefore endogenous NEP attenuates SP-induced plasma extravasation. Thus the continuous infusion of SP stimulates plasma extravasation in the rat pancreas via activation of the NK1-R, and these effects are terminated by both desensitization of the NK1-R and the cell-surface protease NEP.
authors.affiliation: Department of Surgery, University of California School of Medicine, San Francisco, California 94143, USA.
authors.forename: J
authors.initials: J
authors.lastname: Maa
authors.forename: E F
authors.initials: EF
authors.lastname: Grady
authors.forename: E H
authors.initials: EH
authors.lastname: Kim
authors.forename: S K
authors.initials: SK
authors.lastname: Yoshimi
authors.forename: M M
authors.initials: MM
authors.lastname: Hutter
authors.forename: N W
authors.initials: NW
authors.lastname: Bunnett
authors.forename: K S
authors.initials: KS
authors.lastname: Kirkwood
mesh_terms: D000818:Animals; D001713:Biphenyl Compounds / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D001798:Blood Proteins / Q000032:analysis; D002196:Capillaries / Q000294:innervation / Q000502:physiology; D002199:Capillary Permeability / Q000187:drug effects / Q000502:physiology*; D002211:Capsaicin / Q000494:pharmacology; D002462:Cell Membrane / Q000502:physiology; D005070:Evans Blue / Q000493:pharmacokinetics; D006020:Glycopeptides / Q000494:pharmacology; D007262:Infusions, Intravenous; D008297:Male; D015260:Neprilysin / Q000378:metabolism*; D064729:Neurokinin-1 Receptor Antagonists; D009504:Neutrophils / Q000502:physiology; D010179:Pancreas / Q000098:blood supply*; D011480:Protease Inhibitors / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D018040:Receptors, Neurokinin-1 / Q000502:physiology*; D013373:Substance P / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D001713:Biphenyl Compounds; D001798:Blood Proteins; D006020:Glycopeptides; D064729:Neurokinin-1 Receptor Antagonists; D011480:Protease Inhibitors; D018040:Receptors, Neurokinin-1; D013373:Substance P; D005070:Evans Blue; D015260:Neprilysin; D002211:Capsaicin; C008890:phosphoramidon; C066892:CP 96345